Padcev and Acute kidney failure - a phase IV clinical study of FDA data

Summary:

Acute kidney failure is reported as a side effect among people who take Padcev (enfortumab vedotin-ejfv), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Linagliptin, and have Bladder cancer.

The phase IV clinical study analyzes which people have Acute kidney failure when taking Padcev. It is created by eHealthMe based on reports of 2,536 people who have side effects when taking Padcev from the FDA, and is updated regularly.

What is Padcev?

Padcev has active ingredients of enfortumab vedotin-ejfv. eHealthMe is studying from 2,538 Padcev users. Check the latest studies of Padcev.

What is Acute kidney failure?

Acute kidney failure is found to be associated with 2,835 drugs and 4,492 conditions by eHealthMe. Check the latest studies of Acute kidney failure.

On Jul, 18, 2026

2,536 people reported to have side effects when taking Padcev.
Among them, 24 people (0.95%) have Acute kidney failure.

Could Padcev cause Acute kidney failure?

Among these 24 people:

How long have people been on Padcev when they have Acute kidney failure? *

What is the gender of people who have Acute kidney failure when taking Padcev? *

female: 0.0 %
male: 100 %

What is the age of people who have Acute kidney failure when taking Padcev? *

What are other drugs people take besides Padcev? *

Acetaminophen: 3 people, 12.50%
Febuxostat: 3 people, 12.50%
Famotidine: 3 people, 12.50%
Amiodarone Hydrochloride: 3 people, 12.50%
Aspirin: 3 people, 12.50%
Linagliptin: 3 people, 12.50%
Clobetasol Propionate: 2 people, 8.33%
Hydroxyzine Hydrochloride: 2 people, 8.33%
Keytruda: 2 people, 8.33%
Levocetirizine Hydrochloride: 2 people, 8.33%

What are other side effects people have besides Acute kidney failure? *

Myelosuppression (a decrease in the production of blood cells): 6 people, 25.00%
Diarrhea: 5 people, 20.83%
Dehydration (dryness resulting from the removal of water): 5 people, 20.83%
Erythema Multiforme (a type of hypersensitivity reaction): 5 people, 20.83%
Hyperglycemia (high blood sugar): 4 people, 16.67%
Malignant Neoplasm Progression (cancer tumour came back): 4 people, 16.67%
Itching: 3 people, 12.50%
Movement Disorder (neurological syndromes where they may be excess of movement or a paucity of movement that is not connected to weakness): 3 people, 12.50%
Pneumonia Aspiration (bronchopneumonia that develops due to the entrance of foreign materials into the bronchial tree): 3 people, 12.50%
Rashes (redness): 3 people, 12.50%

What are the existing conditions these people have? *

Bladder Cancer: 10 people, 41.67%
Transitional Cell Carcinoma (cancer tumour inner most layer of urinary system): 8 people, 33.33%
Hyperglycemia (high blood sugar): 4 people, 16.67%
Ureteric Cancer: 4 people, 16.67%
Cardiac Failure: 3 people, 12.50%
Neuropathy Peripheral (surface nerve damage): 2 people, 8.33%
Hyperuricaemia (level of uric acid in the blood that is abnormally high): 2 people, 8.33%
Gastritis - Chronic (long lasting inflammation of stomach): 2 people, 8.33%
Metastases To Lymph Nodes (cancer spreads to lymph node): 2 people, 8.33%
Erythema Multiforme (a type of hypersensitivity reaction): 2 people, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Padcev and have Acute kidney failure?

- Check whether Acute kidney failure is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Padcev:

Padcev (2,538 reports)

Browse all side effects of Padcev:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Acute kidney failure:

Acute kidney failure (2,835 drugs)

Browse all the conditions that are associated with Acute kidney failure:

Acute kidney failure (4,492 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on enfortumab vedotin-ejfv (the active ingredients of Padcev) and Padcev (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.